Olmesartán/ Hidroclorotiazida Jubilant (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil / Hydrochlorothiazide, the active ingredient in Olmesartán/ Hidroclorotiazida Jubilant, is an angiotensin II receptor blocker / thiazide diuretic presented as a tablet for oral use. It is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Olmesartán/ Hidroclorotiazida Jubilant as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality‑assurance protocols and adheres to EU‑GMP standards, ensuring product integrity throughout the supply chain. Products are shipped with appropriate documentation to meet regulatory requirements of each destination country.

Olmesartan medoxomil / Hydrochlorothiazide is used to manage hypertension by targeting the renin‑angiotensin system and promoting diuresis. - Hypertension: reduces elevated systolic and diastolic blood pressure. - Essential hypertension: provides long‑term blood pressure control. - Secondary hypertension: assists in managing blood pressure when caused by other conditions.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or weakness. - Increased urination. - Electrolyte disturbances such as low potassium. - Dry mouth.

Serious or Rare Side Effects: - Angioedema or severe swelling. - Marked hypotension. - Acute renal impairment. - Hyperkalemia. - Severe allergic reactions (rash, Stevens‑Johnson syndrome). - Pancreatitis.

Patients should be monitored regularly for blood‑pressure response and renal function. - Monitor blood pressure: ensure therapeutic target is achieved. - Assess renal function: check serum creatinine and eGFR periodically. - Check electrolytes: especially potassium and sodium levels. - Avoid use in pregnancy: drug is classified Category D. - Use caution in elderly patients: increased risk of hypotension. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may cause hyperkalemia. - ACE inhibitors or other ARBs: increase risk of renal dysfunction and hyperkalemia. - NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels and toxicity. - Other antihypertensives: additive blood‑pressure lowering effect. - Corticosteroids: may counteract diuretic effect. - Digoxin: altered serum levels due to electrolyte changes.